The effect of Chlorella pyrenoidosa supplementation on immune responses to 2 days of intensified training by Chidley, Corinna & Davison, Glen
Kent Academic Repository
Full text document (pdf)
Copyright & reuse
Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all
content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions 
for further reuse of content should be sought from the publisher, author or other copyright holder. 
Versions of research
The version in the Kent Academic Repository may differ from the final published version. 
Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the 
published version of record.
Enquiries
For any further enquiries regarding the licence status of this document, please contact: 
researchsupport@kent.ac.uk
If you believe this document infringes copyright then please contact the KAR admin team with the take-down 
information provided at http://kar.kent.ac.uk/contact.html
Citation for published version
Chidley, Corinna and Davison, Glen  (2017) The effect of Chlorella pyrenoidosa supplementation









Eur J Nutr 
DOI 10.1007/s00394-017-1525-9
ORIGINAL CONTRIBUTION
The efect of Chlorella pyrenoidosa supplementation on immune 
responses to 2 days of intensiied training
Corinna Chidley1  · Glen Davison1 
Received: 26 April 2017 / Accepted: 4 August 2017 
© The Author(s) 2017. This article is an open access publication
bouts, but it was higher at some times in the Chlorella group 
(for bouts 2 and 3).
Conclusion Supplementation with Chlorella has beneicial 
efects on resting sIgA, which might be beneicial during 
periods of intensiied training.
Keywords Cycling · Single-celled microalgae · Algae · 
IgA · Exercise · Nutrition
Introduction
It is widely reported that athletes engaged in regular pro-
longed and/or strenuous exercise (e.g. endurance athletes) 
have a higher than normal incidence of upper respiratory 
tract infection (URTI) symptoms (URS), which may be 
related to an exercise-induced impairment of immune func-
tion (immunodepression) [1, 2]. This is thought to be related 
to a high total training load and also the way training is 
distributed or periodised. In support of this, Svendsen et al. 
[3] have recently shown that rapid changes in training load 
(i.e. increasing too quickly) are better predictors of URS risk 
than total training load alone, which agrees with previous 
research in this area [4, 5]. However, many athletes must 
train intensively to be successful. It is also common for ath-
letes to undergo short periods of intensiied training (e.g. 
when training load is rapidly increased intentionally) with 
the aim of enhancing physiological adaptation and perfor-
mance. For this reason, it is inevitable that they will have an 
increased risk of immunodepression and URTI susceptibility 
during and after these times. Hence, any nutritional inter-
vention that can minimise these negative efects will be of 
beneit to such athletes.
Many nutritional interventions have been investi-
gated as potential countermeasures to exercise-induced 
Abstract 
Purpose Periods of intensiied training are associated with 
immune disturbances, The aim was to investigate the efects 
of supplementation with Chlorella pyrenoidosa (Chlorella) 
on secretory IgA (sIgA) responses to 2days intensified 
training.
Methods Twenty-six subjects (age 29.1  ±  8.7  years; 
 VO2max 53.7 ± 11.7 ml kg min
−1) provided resting saliva 
samples for determination of sIgA, at baseline (week-0) and 
following 4, 5, and 6 weeks (weeks-4, -5, -6) of daily supple-
mentation with 6 g/day Chlorella (n = 13) or placebo (PLA, 
n = 13). During week-4 a 2-day intensiied training period 
was undertaken [morning and afternoon sessions each day, 
respectively:  VO2max test; high-intensity interval training 
(HIIT, 3 × 30 s Wingate sprints); 90 min at ~60%  VO2max; 
3 × 30 s HIIT].
Results Chlorella increased resting sIgA secretion 
rate (trial ×  time, P = 0.016: no change with PLA but 
increases with Chlorella at week-4, week-5 and week-
6, P  =  0.020,  <0.001, and 0.016). PLA vs Chlorella: 
week-0 = 54 ± 33 vs 57 ± 37 µg/min; week-4 = 54 ± 35 
vs 83 ± 57 µg/min; week-5 = 63 ± 46 vs 98 ± 47 µg/
min; week-6 = 58 ± 35 vs 85 ± 59 µg/min. Minimal acute 
changes in sIgA were seen in response to individual exercise 
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immunodepression, but the evidence for many is limited 
[6–8]. One food supplement commonly used in Japan, which 
has been suggested to have beneicial efects on immune 
function, is the freshwater single-celled microalgae Chlo‑
rella pyrenoidosa. The efects of Chlorella pyrenoidosa, as 
a nutritional supplement, on immune function have been 
widely investigated. This includes indings of improved 
aspects of mucosal immunity [9–11], enhanced Th1 immune 
responses [12–15], and improved natural killer (NK) cyto-
toxic activity (NKCA, [13]). However, there are relatively 
few studies of humans in vivo, and fewer still on athletes and 
those with high physical activity levels.
Chlorella pyrenoidosa contain a number of vitamins, 
minerals, and amino acids (see Table S1). However, the 
doses consumed with typical daily intakes (e.g. 6 g/day in 
total) are unlikely to be of beneit to individuals who are 
not nutritionally deicient (so many athletes will already be 
abundant in these nutrients from their normal diet). The ben-
eits seen with Chlorella pyrenoidosa supplementation, how-
ever, are more likely caused by other substances which have 
bioactive properties and are bioavailable after consumption. 
It has been shown that many of the polysaccharides and gly-
coproteins (or protein/polysaccharide complexes) found in 
chlorella are responsible for the immunostimulating proper-
ties [16–18]. Indeed, Chlorella pyrenoidosa supplementation 
has been shown to increase both sIgA concentration and 
secretion rate [9, 11] when consumed daily (5–6 g/day) for 
4–8 weeks in healthy humans. One previous study of ath-
letes observed protection against the detrimental efects of 
an intensiied training period on salivary sIgA levels [10]. 
In that study 10 female kendo athletes were supplemented 
with either 6 g/day Chlorella or placebo for 4 weeks ahead 
of a 5-day training camp. Salivary sIgA concentration and 
secretion rates were maintained near baseline levels through-
out the duration of the training camp in the Chlorella group 
compared to the signiicant reductions observed in the con-
trol group. The indings of this study, although in only a 
limited cohort of athletes, demonstrates that chlorella may 
help attenuate immunodepression observed following inten-
siied periods of training. Furthermore, none of the previous 
studies have assessed the response to individual sessions in 
the training period. Hence, the purpose of this study was to 
investigate the efects of Chlorella pyrenoidosa supplemen-




The study was conducted in accordance with the Dec-
laration of Helsinki and approved by the University of 
Kent’s Research Ethics Advisory Group. All subjects were 
informed both verbally and in writing of the nature and 
risks of the experimental procedures after which written 
consent was obtained.
Study design and subjects
Thirty-four healthy and physically active subjects with 
experience of exercise training (i.e. at least three times 
per week of planned physical exercise) volunteered for the 
study (27 males and 7 females). Subjects were excluded 
from participation if they were using nutritional supple-
ments or medication, or if they had given blood, received 
vaccinations, or sufered an infection within 1 month of 
the study commencing. All subjects provided written 
informed consent before participation.
Subjects were randomised to receive 6 g/day chlorella 
(SC, n = 17, 3 female) or placebo (PLA, n = 17, 4 female) 
daily. Treatments were administered in a double-blind man-
ner. A total of 8 subjects were lost to follow-up/withdrew 
before completion of the study due to issues unrelated to 
the study (lack of time or sporting injury) leaving n = 13 
(4 female) in the placebo group and n = 13 (1 female) in 
the chlorella group (however, covariate analysis found no 
inluence of sex on any of the measures so all analyses were 
completed with combined male and female results). Further-
more, physical characteristic proiles and indicators of physi-
ological itness were similar between groups (PLA vs SC, 
respectively: age 31 ± 9 vs 27 ± 9 years, P = 0.204; height 
171 ± 7 vs 175 ± 7 cm, P = 0.170; weight 70.8 ± 12.5 
vs 71.8  ±  9.4  kg, P  =  0.809;  VO2max 50.9  ±  9.9 vs 
57.7 ± 13.2 ml kg−1 min−1, P = 0.153; gas exchange thresh-
old as % of  VO2max 46.3 ± 5.5 vs 44.0 ± 8.0%, P = 0.410).
Supplements
In line with previous research, the inal dose was 6 g per 
day (30 tablets) of Chlorella pyrenoidosa tablets (Sun 
Table 1  Nutritional values of placebo and SunChlorella A tablets
Placebo Chlorella
Energy, kcal/6 g 24.36 23.22
Moisture, g/6 g 0.19 0.29
Protein, g/6 g 0.12 3.28
Fat, g/6 g 0.35 0.71
Total carbohydrate, g/6 g 5.21 1.28
 Sugar, g/6 g 5.14 0.53
 Dietary ibre, g/6 g 0.07 0.75
Ash, g/6 g 0.13 0.43
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Chlorella ‘A’ tablets, Sun Chlorella Corporation, Kyoto, 
Japan) or placebo [9–11] (see Table 1 for nutritional com-
position). The placebo tablets were also provided by Sun 
Chlorella Corporation and were indistinguishable from the 
Chlorella tablets. Supplements were provided in sealed foil 
pouches with a blinding code that was held by the manu-
facturer and not revealed until after all analyses had been 
completed. The dose was gradually increased over the irst 
3 days starting with a total of 10 tablets per day on day 
1, 20 tablets per day on day 2 and 30 tablets per day from 
day 3 and all remaining days during the supplementation 
period. Subjects were advised to swallow their tablets with 
water, consuming half alongside their breakfast and half 
alongside their evening meal for the duration of the study.
URTI questionnaires
Subjects completed the Jackson common cold questionnaire 
[19] and episodes of illness were identiied and scored as 
previously described [20].
Trials
Subjects reported to the laboratory between 06:30 and 
08:30 h following an overnight fast. Baseline saliva samples 
were collected after 10 min of seated rest, and at least half an 
hour after waking [21]. Subjects were provided with the irst 
4 weeks of supplementation, along with illness question-
naires to be completed daily. After 4 weeks of supplementa-
tion they returned for the 2-day intensiied training period. 
Subjects continued to take their supplement and record 
daily illness diaries, for a further 2 weeks after the week in 
which the intensiied training took place. Resting saliva sam-
ples were collected pre-supplementation (Baseline), after 
4 weeks of supplementation, before the intensiied training 
(week-4-day 1), during the intensiied training (resting, pre-
exercise on day 2: week-4-day 2) and 1, and 2 weeks after 
the intensiied training (week-5 and week-6, respectively). 
Additional samples were also obtained immediately before 
(Pre-Ex), after (Post-Ex) and 1 h after (1 h Post-Ex) each 
training session of the intensiied period.
Exercise trials
2‑day intensiied training period
After 4 weeks of daily supplementation subjects undertook 
4 exercise bouts in 2 days, one in the morning and one in 
the afternoon of each day (sessions 1–4). Session 1 was an 
incremental maximal oxygen uptake test; session 2 a high-
intensity interval training (HIIT) session; session 3 a pro-
longed endurance ride; and session 4 a second HIIT session.
Day 1 On the irst day subjects reported to the labora-
tory between 06:30 and 08:30 h following an overnight fast. 
Height and weight were recorded and subjects were itted 
with a heart rate monitor (Polar Electro, Kempele, Finland), 
and facemask (Cortex Biophysik GmbH, Leipzig, Germany) 
connected to a breath-by-breath gas analyser (MetaLyzer 
3BR2, Cortex Biophysik GmbH, Leipzig, Germany). Sub-
jects completed a ramped incremental V̇O
2 max
 test until 
volitional exhaustion on an electronically braked cycle 
ergometer (Excalibur Sport, Lode, Groningen, the Nether-
lands), beginning with 3 min of unloaded cycling before 
initiation of a continuous increment in work load of 30 W/
min until volitional exhaustion. Subjects’ V̇O
2 max
, and irst 
gas exchange threshold were identiied from the test data 
collected so that 25% of the diference between these val-
ues (Δ) could be calculated (the power output associated 
with 25% Δ was used for the prolonged endurance bout the 
next day). Subjects were allowed to return home following 
post-exercise sample collections, and then reported to the 
laboratory again between 16:00 and 18:00 h having refrained 
from eating within the hour preceding the test. A friction-
braked cycle ergometer (Monark Ergomedic 874e; Monark 
Exercise AB, Vansbro, Sweden) was prepared and the bas-
ket loaded with 7.5% of the subject’s body mass. Subjects 
then performed a 5-min warm-up at 70 rpm with the bas-
ket suspended (with a 5-s sprint against 7.5% body weight 
resistance at 3 min). After 2 min of passive recovery seated 
on the ergometer, subjects performed three 30-s maximal 
(‘all-out’) sprints with 90-s recovery between each. Subjects 
were allowed to bring their cadence up to 70 rpm before the 
basket was released, at which point they were required to 
sprint maximally (all-out efort) for 30 s. Following each 
sprint, subjects were asked for their rating of perceived exer-
tion (RPE) for the sprint just completed [22].
Day 2 Subjects once again reported to the laboratory 
between 06:30 and 08:30 h following an overnight fast. Sub-
jects were itted with a heart rate monitor (Polar Electro, 
Kempele, Finland). Subjects cycled for 90 min at 25% Δ, 
the intensity of which was validated within the irst 10 min 
by monitoring V ࡆO2 responses, and the intensity adjusted 
accordingly (subjects were monitored continually during the 
irst 10 min using the online system; MetaLyzer 3BR2, Cor-
tex Biophysik GmbH, Leipzig, Germany); expired gas was 
collected into Douglas bags (Plysu Industrial, Ltd., Milton 
Keynes, UK) every 20 min thereafter for analysis of  FEO2 
and  FECO2 using a gas analyzer (Servomex, West Sussex, 
UK) and volume measured using a dry gas meter (Harvard 
Apparatus, Kent, UK) to determine gas exchange variables 
as previously described [23], RPE and heart rate (HR) were 
recorded every 10 min. A water bolus of 2 mL kg−1 body 
mass was provided every 15 min. Following post-exercise 
samples subjects were once again allowed to leave the lab-
oratory and return later the same day between 16:00 and 
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18:00 hours having refrained from eating in the hour pre-
ceding exercise. Subjects then completed an identical HIIT 
protocol to the one undertaken the previous day.
Sample collection and analytical methods
Saliva samples were collected as previously described [24]. 
Briefly, timed, unstimulated whole saliva was obtained 
whilst subjects were seated, with the head tilted slightly 
forward and making minimal orofacial movement. They 
were asked to swallow to empty the mouth, before whole 
saliva was collected by passive dribble into a pre-weighed 
sterile tube for an initial period of 2 min. If insuicient saliva 
was obtained after the initial 2-min period the process was 
repeated. Prior to samples being collected, subjects rinsed 
their mouth with fresh tap water and remained seated for 
10 min. The tube was re-weighed after collection of the 
sample so that saliva volume (and hence low rate) could be 
estimated. Tubes were weighed to the nearest 0.1 mg (saliva 
density was assumed to be 1.00 g ml−1). Saliva samples were 
centrifuged in a micro-centrifuge at 17,000×g for 5 min, and 
the supernatant stored in aliquots at −80 °C until analysis 
of sIgA by sandwich ELISA (modiied from Leicht et al. 
[25], but using a capture antibody speciic to secretory IgA, 
I-6635, Sigma-Aldrich, St. Louis, MO, USA).
Statistics
All results are presented as mean (SD). An alpha-priori level 
of 0.05 was set for determination of statistical signiicance. 
Normality of the distribution of data was assessed using the 
Shapiro–Wilk test. Normally distributed variables (subject 
characteristics, exercise trial physiological responses, ill-
ness duration, and symptom score) were compared using 
independent samples t-tests. Number of illness episodes 
were compared using the Chi-squared test with the Fisher’s 
exact test. Variables that were not normally distributed (and 
could not be normalised via transformation) were assessed 
with appropriate non-parametric tests. Mann–Whitney U 
tests were undertaken for age; RPE of the 90-min trial; and 
severity of illness. All other variables were compared (across 
time, between groups) using two-way mixed ANOVA. 
Where necessary, post hoc follow-up was conducted with 
Holm–Bonferonni corrected t-tests. All tests were carried 
out using SPSS Version 22.0 (IBM Corp, Armonk, NY, 
USA). As previously mentioned, due to diferent numbers 
of females in each group (after drop-out from the original 
n = 34) covariate analysis was performed, revealing no inlu-
ence of sex on the between-group comparisons and so all 
analyses are reported for males and females combined (com-
paring only supplementation group, SC vs PLA).
Results
Physiological and perceptual responses to exercise bouts
The results from the incremental  VO2max test are reported 
above in the “Study design and subjects” section of the 
“Methods”. In addition, the mean duration of each test 
(total exercise time to the point of volitional exhaustion) 
was similar between groups (PLA 13.1 ± 2.0 min vs SC 
14.4 ± 1.8 min, P = 0.109).
Physiological and perceptual responses related to the 
demands of the 90-min continuous exercise trial were 
similar between groups (mean values for the bout in PLA 
vs SC, respectively: heart rate 133 ± 12 vs 138 ± 15 beats/
min, P = 0.378; RPE 13 ± 1 vs 13 ± 1, P = 0.762; trial 
 VO2 2.2 ± 0.4 vs 2.3 ± 0.5 L min
−1, P = 0.190; respira-
tory exchange ratio (RER) 0.95 ± 0.07 vs 0.92 ± 0.04, 
P = 0.344; exercise intensity as % of  VO2max 60.5 ± 5.9 
vs 60.1 ± 10.4%, P = 0.979).
For the HIIT sessions no physiological measures were 
recorded, but subjects were instructed to give maximal 
and ‘all-out’ efort (without any pacing and not holding 
back anything for later in the test) for each sprint repeti-




Resting salivary IgA concentration (Fig. 1) showed a sig-
niicantly diferent pattern of change over the course of 
the study (2-way mixed ANOVA trial × time interaction 
P = 0.022). Post hoc analysis revealed no changes in the 
PLA group and a signiicant time efect (P < 0.001) in the 
SC group (but when followed with further post hoc tests 
Fig. 1  Resting saliva sIgA concentration over study period
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this only revealed a trend for an increase in the weeks 
after intensiied training (week-5 P = 0.078, and week-6 
P = 0.056). Resting sIgA secretion rate (Fig. 2) showed 
a signiicantly diferent pattern of change over the course 
of the study (trial × time interaction P = 0.016). Post hoc 
analysis revealed no changes in the PLA group and a sig-
niicant time efect (P = 0.002) in the SC group, which 
was due to an increase over baseline values at the week-
4-day 1 (P = 0.020), week-4-day 2 (P = 0.006), week-5 
(P < 0.001), and week-6 (P = 0.016) time points. 
Responses to exercise
During the intensiied-training period, there were signiicant 
decreases in salivary sIgA concentration in response to some 
of the exercise bouts (time efects for bouts 1–4: P < 0.001, 
P < 0.001, P = 0.007, and P < 0.001, respectively), but SC 
did not inluence this (trial × time interaction, all P > 0.05) 
(Table 1). When normalised against low rate (i.e. secre-
tion rate) there was no trial × time interaction for exercise 
bouts 1 or 4 (P = 0.066, P = 0.181, respectively). However, 
there was a signiicant trial × time interaction for exercise 
bouts 2 (P = 0.016) and 3 (P = 0.017). For bout 2 (1st high-
intensity interval training session) post hoc analysis revealed 
no change in the PLA group (P = 0.075) but a signiicant 
time efect in the SC group (P = 0.003). Further post hoc 
analysis showed an increase above baseline at the pre-exer-
cise (P = 0.009) and post-exercise (P = 0.010) times. For 
exercise bout 3 (90 min ride) post hoc analysis revealed no 
change in the PLA group (P = 0.996) but a signiicant time 
efect in the SC group (P < 0.001). Further post hoc analy-
sis showed an increase above baseline at the pre-exercise 
(P = 0.023), post-exercise (P = 0.005), and 1 h post-exercise 
(P = 0.004) times (see Table 2).
Fig. 2  Resting saliva sIgA secretion rate over study period. Aster‑
isk (P < 0.05) indicates signiicantly higher than baseline (post hoc 
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URS reports
There was no diference between groups (P = 1.000) in the 
number of URS episodes sufered in the 2 weeks following 
the training, with 31% of subjects in each group reporting 
an episode. The duration of URS episodes was also not dif-
ferent between groups (5 ± 2 days PLA vs 8 ± 5 days SC, 
P = 0.333). There was also no diference between groups 
for mean severity ratings (1.8 ± 0.5 PLA vs 2.0 ± 1.2 SC, 
P = 0.711) or total symptom scores (10.5 ± 7.0 PLA vs 
21.5 ± 13.0 SC, P = 0.187) of URS episodes.
Discussion
The primary aim of the current study was to assess the efects 
of chlorella supplementation on salivary sIgA in response to 
a 2-day intensiied training period. The main indings were 
that daily supplementation with SC for 4 weeks before (and 
2 weeks after) the 2-day intensiied training period increased 
resting sIgA concentration (by week-5) and secretion rate 
(by week-4). There were no efects on acute responses of 
sIgA concentration to each of the exercise bouts during 
the intensiied training period, but sIgA secretion rate was 
increased during some components of the training period in 
the SC compared to PLA group. There were no diferences, 
however, between PLA and SC groups in self-reported URS 
incidence or symptom duration.
The acute decreases in salivary sIgA concentration seen 
after some of the exercise training sessions are in line with 
some previous studies on intensive interval training proto-
cols [26] but not others [24] in which no acute decreases 
were seen for sIgA. On the other hand, the lack of an acute 
efect of each bout on salivary sIgA secretion rate difers 
from Hall et al. [26] but agrees with Davison et al. [24]. 
Few studies, however, have assessed the acute responses 
to multiple exercise sessions over a short time period (e.g. 
intensiied training or training camps). Papacosta et al. [27] 
and Otsuki et al. [10] have shown decreases in resting sIgA 
levels over longer periods of intensiied training/training 
camps (i.e. 1–2 weeks in duration), which difers to the 
present study in which no decreases in resting sIgA con-
centration or secretion rate were seen during (week-4-day 
2) or shortly after (week 5), but this is possibly due to the 
shorter intensiied training period in the present study. The 
previous studies did not assess the response to individual 
sessions in the training period, however, which represents a 
novel aspect of the current study. sIgA is one of the body’s 
irst lines of defence against pathogens entering through the 
oral cavity. A decrease in sIgA has been shown to be related 
to an increased risk of developing URTI and the associated 
symptoms (URS). For this reason, it was hypothesised that 
any increase in sIgA would translate to a reduced risk of 
URS (lower incidence of self-reported episodes), in line with 
previous studies on intensiied periods of training/training 
camps or long-term monitoring of athletes (e.g. [28–31]). 
However, a limitation of the present study is that the rela-
tively modest sample size (n = 26) combined with the rela-
tively low number of total URS episodes experienced during 
the study period (31% incidence rate) may limit our ability 
to comprehensively determine the efects on URTI/URS. 
Furthermore, resting sIgA levels remained relatively stable 
in the PLA group and decreases were only evident acutely 
after some, but not all, of the exercise training sessions. This 
maintenance of sIgA defences, close to baseline levels, in the 
subjects of this study may mean that URTI/URS risk was not 
adversely afected to a great extent even with the intensiied 
training period. Despite this, our indings (in combination 
with those from previous research) do show some beneits 
from SC in terms of increases, above baseline levels, in sali-
vary sIgA. Importantly, resting sIgA concentration was not 
signiicantly increased before or during the intensiied train-
ing period, but appeared to be increasing in the weeks after. 
It is possible therefore that more beneit would be evident 
with a longer supplementation period (e.g. if the intensiied 
training was commenced after 5 or 6, rather than 4, weeks 
of supplementation) and it is feasible that this would also 
translate to a greater efect on URS reports. However, this 
will require further study.
The most likely mechanisms for the increase in salivary 
sIgA observed after 4–5 weeks of supplementation with 
Chlorella are via the immunostimulating properties of com-
pounds found in chlorella such as speciic polysaccharides 
and glycoproteins or protein/polysaccharides complexes 
[16–18]. In particular, Kralovec et al. [18] identiied rela-
tively high molecular weight (>100 kDa) protein/polysac-
charide complexes and polysaccharides as being responsible 
for the immunostimulatory efects of Chlorella pyrenoidosa 
in vitro. They identiied glutamic acid and aspartic acid as 
the major amino acid constituents of the protein/polysac-
charide complexes (~22–26%) with galactose (~22–50%), 
rhamnose (~18–40%) and arabinose (~14–26%) as the main 
constituent monosaccharides found in the polysaccharides 
and protein/polysaccharide complexes with the greatest 
immune stimulating activity. This included efects on B cell 
stimulation and proliferation, which could explain the ben-
eicial efects seen in humans in vivo, including antibody 
response to inluenza vaccination (e.g. [32]) and aspects of 
mucosal immunity as observed in the present study and pre-
vious research (e.g. [9–11]). However, it is not possible to 
determine the precise mechanisms and we can only specu-
late at this stage. Indeed, Chlorella does contain an abun-
dance of nutrients, many of which could inluence immunity 
in athletes. However, in line with previous suggestions [9, 
10] the speciic doses of each of these nutrients are unlikely 
to be responsible for the efects we have observed on sIgA 
Eur J Nutr 
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in a healthy young adult population with no known dietary 
deiciencies. As such, we suggest that it is the compounds 
such as polysaccharides and protein/polysaccharide com-
plexes (as identiied by Kralovec et al. [18]) that are respon-
sible for the efects observed in the present study. This will 
require further study (including the determination of the bio-
availability from orally consumed Chlorella and monitoring 
levels of these substances in plasma and/or immune cells 
after ingestion, but this was beyond the scope of the current 
investigation).
Limitations
One limitation of this study is that we did not measure 
 VO2max pre-supplementation, so it is not possible to see 
the efect of SC supplementation on these parameters. This 
study was not designed to measure cardiovascular responses 
to supplementation however, but rather the immunological 
responses to a controlled period of intensiied training (i.e. 
with all participants exposed to the same relative training 
demand). We also did not record physiological responses 
during HIIT sessions to ensure that the exercise intensity 
was comparable between PLA and SC groups. However, we 
are conident that subjects produced a maximal efort (and 
hence the same relative demand) for these sessions based 
on the maximal RPE values expressed following all HIIT 
sprints.
In summary, daily supplementation with SC was able to 
increase salivary sIgA concentration and secretion rate at 
rest. Together with previous research there is now substan-
tial evidence to show that SC can enhance salivary sIgA; 
however, in the present study it appears that a longer sup-
plementation period may be required in order to translate to 
protection against URTI and reduced URS reports.
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